Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain.
Blancas I, Grosjean J, Pedersini R, Buzzoni C, Sleilaty G, Molero A, Tamma A, Chouaki N, Atienza M, Emde A, Siddi S, Sanchez Bayona R, Del Mastro L, Fakhouri W. Blancas I, et al. Among authors: del mastro l. Future Oncol. 2024;20(31):2371-2384. doi: 10.1080/14796694.2024.2368455. Epub 2024 Aug 8. Future Oncol. 2024. PMID: 39115881 Free PMC article.
Randomized cooperative study of perioperative chemotherapy in breast cancer.
Sertoli MR, Bruzzi P, Pronzato P, Queirolo P, Amoroso D, Del Mastro L, Venturini M, Vigani A, Bertelli G, Campora E, et al. Sertoli MR, et al. Among authors: del mastro l. J Clin Oncol. 1995 Nov;13(11):2712-21. doi: 10.1200/JCO.1995.13.11.2712. J Clin Oncol. 1995. PMID: 7595729 Clinical Trial.
Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L. Lambertini M, et al. Among authors: del mastro l. Oncologist. 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22. Oncologist. 2015. PMID: 26099741 Free PMC article.
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L. Lambertini M, et al. Among authors: del mastro l. Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11. Clin Breast Cancer. 2017. PMID: 28479052
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Among authors: del mastro l. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
345 results